BioSyent Inc. (CVE:RX - Get Free Report) shares hit a new 52-week high during trading on Friday . The company traded as high as C$11.98 and last traded at C$11.95, with a volume of 1111 shares trading hands. The stock had previously closed at C$11.61.
BioSyent Trading Up 3.2 %
The company has a fifty day moving average of C$11.21 and a 200-day moving average of C$10.54. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The firm has a market capitalization of C$138.85 million, a PE ratio of 19.97 and a beta of 0.93.
Insider Activity
In other BioSyent news, Senior Officer Robert Joseph March sold 4,775 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 230,800 shares of the business's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. In the last 90 days, insiders have sold 239,132 shares of company stock worth $2,661,482. 33.65% of the stock is owned by corporate insiders.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Further Reading
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
